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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
1. To assess the efficacy and feasability of CBT (CT, BT, CBT and third wave CBT interventions) for different anxiety disorders in
older adults aged 55 years or over compared with minimal management
2. To assess the efficacy and feasibility of CBT (CT, BT, CBT and third wave CBT interventions) for different anxiety disorders in
older adults aged 55 years or over compared with other psychological therapies
3. To conduct a narrative review to additionally describe trials omitted from the quantitative analysis due to missing data.
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B A C K G R O U N D
Description of the condition
Patients with anxiety complain of tension or restlessness, or they
exhibit jitteriness, autonomic hyperactivity, vigilance, insomnia,
distractibility, shortness of breath, numbness, apprehension,worry
or rumination. Although most people experience such symptoms,
an anxiety disorder is suspected when symptoms become dispro-
portionately severe compared to their problems. According to the
criteria of the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM), anxiety disorders in later life are classified similarly to
those in adult life and include panic disorderwith andwithout ago-
raphobia, generalised anxiety disorder, social phobia, specific pho-
bia, obsessive-compulsive disorder, and post-traumatic and acute
stress disorder (APA 1980, APA 1987, APA 1994). Pure anxiety
disorders in later life are rare, as most patients have a comorbid
second anxiety disorder or depressive disorder (Flint 2005; Kessler
2005a; Lenze 2005; van Balkom 2000).
The prevalence rate of anxiety disorders among older adults living
in the community has been estimated between 10 and 15%, with
generalised anxiety disorder, panic disorder and specific phobias
being the most common (Beekman 1998; Kessler 2005b). In later
life, anxiety disorders impair quality of life by having a negative
impact on functioning, well-being, andmedical consumption (De
Beurs 1999;Wetherell 2005b; van Zelst 2006).Moreover, patients
suffering fromanxiety disorders have an increased risk of becoming
depressed (Beekman 2000), and left untreated, anxiety disorders
tend tobecome chronic (Larkin 1992). In two large cohort-studies,
anxiety disorders in later life were prospectively associated with an
increased mortality rate (van Hout 2004; Brenes 2007).
Description of the intervention
First line treatment for anxiety disorders consist of psychologi-
cal treatment or antidepressant drugs (van der Velde 2003; NICE
2007). Community studies show that only 5.1% of older adults
suffering from anxiety disorders receive psychological treatment
and only 3.8% are prescribed an antidepressant drug (De Beurs
1999). Both patient and physician characteristics may contribute
to this phenomenon.Many older adults resist the use of antidepres-
sants based on fear of dependence, prior negative experiences, resis-
tance to viewing their symptoms as a medical illness, and concern
that antidepressants will prevent natural feelings (Givens 2006).
The average duration between anxiety symptom onset and first
treatment contact has been shown to be between 9 and 23 years,
suggesting general practitioners do not easily recognise anxiety dis-
orders (Wang 2005;Kroenke 2007). The referral rate fromprimary
care to amental health specialist is three times lower for older adults
suffering from anxiety disorders (17%) compared to those suffer-
ing from depression (55%) (Ettner 1997). Furthermore, general
practitioners themselves may be reluctant to prescribe drugs for
anxiety symptoms being afraid for increased side-effects in later
life, for example the increased risk of falling and traffic accidents,
memory impairment, and dependency associated with the use of
benzodiazepines (Gorgels 2001) and hyponatraemia with the use
of serotonin reuptake inhibitors (Wright 2008). Also of concern
are the adverse effects of drug interactions, such as gastrointestinal
bleeding resulting from the concurrent use of serotonin reuptake
inhibitors and non steroidal anti-inflammatory drugs in this age
group known for polypharmacy use (Yuan 2006; Weinrieb 2005).
As effective management of anxiety disorders in later life may im-
prove outcome, it is important that guidelines for treatment be-
come available.
Cognitive-behavioural therapy (CBT) combines principles of both
behavioural and cognitive therapy. Cognitive therapy (CT) as-
sumes that a patient’s symptoms (e.g., anxiety) arise from mis-
perceptions and attitudes about the world and themselves (Beck
1995). Behavioural therapy (BT) is a directive, active approach
involving principles of learning to help the patient develop new
and adaptive ways of behaving (Bandura 1969; Yates 1970). As
a psychotherapy, CBT is characterised as a structured, goal-ori-
ented, problem-focused, time-limited intervention (Korrelboom
2004).
In order to deal with age-associated cognitive impairment, some
authors argue for inclusionof learning andmemory aids like home-
work reminders, troubleshooting calls or weekly review of all con-
cepts and techniques (Mohlman 2003). Recent RCTs on older
adults, however, remain inconclusive onwhether age-related adap-
tations of psychotherapeutic techniques are necessary to remain
efficacious for anxiety disorders in later life (Stanley 2003a; Stanley
2003b; Wetherell 2005a).
How the intervention might work
CBT identifies habitual ways in which patients distort informa-
tion (e.g., automatic thoughts) and teaches patients to identify
and respond to their dysfunctional thoughts and beliefs, using a
variety of techniques to change thinking, mood, and behavior. Be-
havioural interventions help the patient develop new and adap-
tive ways of behaving. Exposure based treatment utilises gradual,
systematic, repeated exposure to the feared object or situation to
desensitise patients with anxiety disorders to the feared stimulus.
The controlled exposures are predictable and the patient is taught
a variety of adaptive coping strategies.
Why it is important to do this review
CBT is generally considered the most effective psychotherapy for
anxiety disorders (van der Velde 2003). The efficacy of CBT for
anxiety disorders in young and middle-aged adults is supported by
a variety of meta-analyses (Bakker 1998; Mitte 2005a; Furukawa
2006; Mitte 2005b; Westen 2001). However, whether these re-
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sults also apply to older adults remain unclear since most trials
exclude participants over the age of 65 years (Wetherell 2003).
Generalisation of meta-analytic studies in young and middle-aged
adults to older adults is limited, as older adults often have more
chronic disorders, which are presumed to be more treatment resis-
tant (Katz 2002). Therefore, the current review aims to provide a
comprehensive and up to date summary of the available evidence
on CBT as a treatment for older adults.
Many of the earlier studies regarding the psychological treatment
of anxiety disorders in later life suggest efficacy for CBT, but have
been limited to subclinical anxiety and lack rigorous inclusion cri-
teria, like the presence of an anxiety disorder according to diag-
nostic guidelines (Nordhus 2003). Recent reviews generally con-
clude psychological treatment is effective for anxiety disorders in
later life, but also conclude that there is a need for large, rigorous
controlled trials for the different anxiety disorders (Nordhus 2003;
Pinquart 2007; Ayers 2007). However, in later life, pure anxiety
disorders are rare, as most patients have a comorbid second anxiety
disorder or depressive disorder. For the purposes of conducting the
current review, therefore, generalised anxiety disorder, panic dis-
order with and without agoraphobia and social phobia, conditions
that often overlap, will be combined into one single diagnostic
category called anxiety disorders. Obsessive-compulsive disorder
and the stress disorders, acute and post-traumatic stress disorder,
will be considered as separate diagnostic categories.
O B J E C T I V E S
1. To assess the efficacy and feasability of CBT (CT, BT, CBT
and third wave CBT interventions) for different anxiety
disorders in older adults aged 55 years or over compared with
minimal management
2. To assess the efficacy and feasibility of CBT (CT, BT, CBT
and third wave CBT interventions) for different anxiety
disorders in older adults aged 55 years or over compared with
other psychological therapies
3. To conduct a narrative review to additionally describe trials
omitted from the quantitative analysis due to missing data.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) will be included. In the
case of cross-over trials (a rare feature within this field of research),
only the first randomisation period will be included in the review.
Studies using a quasi-randomised design will be excluded. Cluster
RCTs, in which centres or therapists were randomised to interven-
tion or control groups will be included, provided that the specific
aim of the study was to examine the effect of the intervention.
Types of participants
All RCTs of older people (55 years or older) with a primary diag-
nosis of an anxiety disorders according to DSM-III (APA 1980),
DSM-III-R (APA 1987), DSM-IV (APA 1994), ICD-9 (ICD-9
1979), ICD-10 (ICD-10 1999) diagnostic criteria will be consid-
ered for inclusion, irrespective of culture and setting.
The review will combine generalised anxiety disorder, panic disor-
der with and without agoraphobia and social phobia, conditions
that often overlap, into one single category called anxiety disor-
ders. Obsessive-compulsive disorder (OCD) and the stress disor-
ders, acute and post-traumatic stress disorder, will be considered
separately. OCD is often hypothesised to be part of an obsessive-
compulsive symptom spectrum, including body dysmorphic dis-
order, hypochondriasis, eating disorders, tic disorders and autism
(Bartz 2006). Moreover, OCD is more treatment resistant com-
pared to other anxiety disorders, and pharmacological treatments
may be different from the other anxiety disorders, since they in-
clude the use of antipsychotics where there is treatment resistance
and benzodiazepines are not effective agents (Bandelow 2008; van
der Velde 2003). Posttraumatic stress disorder and acute stress dis-
order is reviewed and analysed separately due to its causal relation-
ship with psycho-traumatic events prior to the onset of the disor-
der. A similar distinction is made by International Classification of
Diseases (ICD-9 1979; ICD-10 1999), acknowledging four cat-
egories of anxiety disorders, namely 1) phobic anxiety disorders,
2) other anxiety disorders (together comparable to our category
’anxiety disorders’), 3) obsessive-compulsive disorders and 4) reac-
tion to severe stress and adjustment disorders. For the purposes of
this review, the three anxiety disorder categories (anxiety disorders,
OCD and PTSD) will be stratified in analyses.
Of studies that include both the target population and younger
participants, the relevant data will be included on the condition
that randomised age blocks have been used and data are reported
in age-blocks.
Studies concerning anxiety symptoms that are part of the clini-
cal presentation of another primary diagnosis (e.g. substance use
disorders, major depression) will be excluded, as well as studies
involving patients with a comorbid psychiatric diagnosis of sub-
stance-related disorder, schizophrenia or psychotic disorder. How-
ever, studies involving participants with comorbid physical ill-
nesses will be eligible for inclusion to increase generalisability, as
most older people suffer from physical illnesses.
Types of interventions
Experimental intervention
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Cognitive therapy (CT) is defined as cognitive restructuring of ir-
rational andmaladaptive anxiety beliefs. Behavioural therapy (BT)
is defined as some form of exposure and/or relaxation exercises.
Cognitive-behavioural therapy (CBT) is defined as delivering a
combination of both CT and BT. In studies where behavioural ex-
periments are included, the therapy will be considered to be CBT,
because behavioural experiments are exercises of new behaviour
(BT) designed to challenge irrational or maladaptive beliefs (CT).
Studies including ‘third wave’ CBT interventions (e.g. mindful-
ness, acceptance and commitment therapy) will also be included.
A minimum number of six therapy sessions has to be delivered,
either in an individual or group format.
Comparator interventions
Non-CBT psychological therapies and minimal management will
be included as control interventions. Non-CBT psychological
therapies include non-directive (supportive) therapies, psychody-
namic therapy and interpersonal psychotherapy. Minimal man-
agement (also sometimes described in trials as standard care, treat-
ment as usual or waiting list), is defined as being elements of clinic
attendance, investigation, reassurance, and simple advice, without
explicit psychological therapy, and also may include naturalistic
prescribing of medication and/or other interventions.
Combination therapy
CBT in combination with pharmacological treatment will be ex-
cluded, as its superior effects over the monotherapies (van Balkom
1997; Bakker 1998) have been challenged by recent meta-analyses
(Furukawa 2006; Mitte 2005a; Mitte 2005b).
Main comparisons
1. CBT, stratified as CBT, BT, CT and third wave CBT
interventions versus minimal management
2. CBT, stratified as CBT, BT, CT and third wave CBT
interventions versus all non-CBT psychological therapies
Types of outcome measures
Primary outcomes
The principal outcome used in this review will be anxiety, mea-
sured as follows:
1. Reduction in anxiety severity (continuous), measured by a
well-validated, observer rated instrument like the Hamilton
Rating Scale for Anxiety (Hamilton 1959), or if not available, a
well validated self-report instrument measuring general anxiety
like the Beck Anxiety Inventory (Beck 1988a). Validated
disorder-specific instruments for obsessive-compulsive disorder
or posttraumatic stress disorder will be used.
2. Clinical recovery or improvement (dichotomous), based on
diagnostic interview or defined cut-off on validated scales, as
specified by trial authors. In case the Clinical Global Impression
scale [change item] (CGI-C) is used, responders are defined as
having a change score of 1 = ‘very much’ or 2 = ‘much’ improved
(Guy 1976).
Secondary outcomes
The following secondary outcome measures will included in the
review:
1. Worrying, assessed continuously by well-validated, self-
report questionnaires, like the Penn State Worrying
Questionnaire (Meyer 1990; van Rijsoort 1999).
2. Depression, assessed continuously by well-validated, self-
report questionnaires, like the Beck Depression Inventory (Beck
1988b).
3. Anxiety, assessed continuously by well-validated observer-
rated or self-report questionnaires, in studies of obsessive-
compulsive disorder or posttraumatic stress disorder
4. Dropout rate will be included as a surrogate measure of
feasibility of cognitive-behavioural therapy, in lieu of other more
direct indicators of feasibility.
5. Occurrence of adverse events
6. Quality of life, assessed continuously by well-validated, self-
report questionnaires, like the SF-36 (Ware 1992).
Search methods for identification of studies
A number of sources will be used to identify studies for possible
inclusion in this review (see below). Studies will not be limited to
any particular language.
Electronic searches
The Cochrane Collaboration Depression, Anxiety and Neurosis
Controlled Trials Register (CCDANCTR) will be searched using
the following terms:
CCDANCTR-Studies
Diagnosis = Anxiety or Anxious or Phobi* or Panic or Obsess* or
Compulsi* or Post-Traumatic and Age-Group = Aged and Inter-
vention = *Therapy
CCDANCTR-References
Keyword = Anxiety or Anxious or *phobi* or “Panic Disorder”
or “Obsessive Compulsive Disorder” or “Post-Traumatic Stress
Disorders and Free-text = Elder* or Geriatri* or Senil* or Older
or ”Old Age“ or ”Late Life“ or ”Aged, 80-And-Over“
A search of PubMed and of PsycINFO (which includes Disserta-
tion Abstracts Internal, a database of unpublished dissertations)
will also be conducted. The following keywords will be used ”late-
life”, “Elderly”, “Aged”, “Aged, 80 years and over“, “Old Age”,
”Anxiety disorder”, ”Anxiety”, “Panic”, “Agoraphobia”, “Phobia”,
“Obsessive-compulsive”, “Posttraumatic”, “psychotherapy”, “cog-
nitive therapy”, “behavior therapy”, “cognitive behavior therapy”.
See Appendix 1 for the exact search strings that will be used in the
different databases.
Searching other resources
Correspondence
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Experts in this field and principal authors who have published
controlled trials in the field of late-life anxiety will be asked if they
knowof any studywhichmeets the inclusion criteria of this review.
Reference lists
Citation lists of potentially relevant papers obtained by thesemeth-
ods will be searched for further relevant trials, as will be the refer-
ence lists of those further relevant trials. In addition, the citation
lists of relevant and recent systematic reviews were perused.
Data collection and analysis
Selection of studies
RCTs that have been identified will be independently assessed for
inclusion by two review authors (RCOV & GJH), based on in-
formation included in the abstract and/or main body of the trial
report. RCTs that both raters regard as satisfying the inclusion
criteria specified in the “Criteria for selecting studies” section will
be collated by the raters (see above). If the raters disagree, the final
rating will be made by consensus, if necessary with the involve-
ment of another member of the review group (AJLMvB). Non-
congruence in selection of trials will be reported as percentage dis-
agreement. Considerable care will be taken to exclude duplicate
publications.
Data extraction and management
Spreadsheet forms will be designed for the purpose of recording
descriptive information, summary statistics of the outcome mea-
sures, the quality scale ratings, and associated commentary. These
data will then be exported to RevMan. Where information is miss-
ing, the reviewers will contact investigators by letter or email in
an attempt to obtain it.
The following data will be extracted from each trial by two review
authors independently (RCOV & GJH):
1. Description of the trials, including primary researcher and
year of publication.
2. Characteristics of the interventions, including the number
of participants randomised to CBT-condition and control
groups, therapy-characteristics, including, the number of sessions
provided, groups versus individual therapy, and components of
the therapy (psycho-education, relaxation training, anxiety
management, type(s) of exposure, cognitive techniques, and
behavioural experiments), and finally the classification in CT,
BT, CBT or third wave CBT interventions.
3. Characteristics of trial methodology, including the
diagnostic and exclusion criteria employed, the screening
instrument used, the inclusion of comorbidity, a minimal
severity criterion, and the number of centres involved.
4. Characteristics of participants, including their gender
distribution, mean age, and the duration of primary symptoms.
5. Outcome measures employed, and summary continuous
(means and standard deviations) and dichotomous (number of
responders) data. Additional information will be included, such
as whether the data reflected the intent-to-treat (ITT) with either
last observation carried forward (LOCF), or completer/observed
cases (OC) sample, and the dropout rates of participants
randomised to the experimental and control groups.
Assessment of risk of bias in included studies
Risk of bias will be assessed for each included study using the
Cochrane Collaboration ’risk of bias’ tool. The following six do-
mains will be considered:
1. Sequence generation: Was the allocation sequence
adequately generated?
2. Allocation concealment: Was allocation adequately
concealed?
3. Blinding of participants, personnel and outcome assessors
for each main outcome or class of outcomes: Was knowledge of
the allocated intervention adequately prevented during the study?
4. Incomplete outcome data for each main outcome or class of
outcomes: Were incomplete outcome data adequately addressed?
5. Selective outcome reporting: Are reports of the study free of
suggestion of selective outcome reporting?
6. Other sources of bias: Was the study apparently free of
other problems that could put it at a high risk of bias?
A description of what was reported to have happened in each study
will be provided, and a judgement on the risk of bias will be made
for each domain within and across studies, based on the following
three categories:
A. Yes (low risk of bias)
B. Unclear
C. No (high risk of bias).
Two independent review authors (RCOV & GJH) will assess the
risk of bias in selected studies. Any disagreement will be discussed
with a third review author (AJLMvB). Where necessary, the au-
thors of the studies will be contacted for further information.
Measures of treatment effect
Dichotomous outcomes
These outcomes will be analysed by calculating a pooled relative
risk (RR) for each comparison, with 95% confidence intervals.
Where overall results are significant, the number-needed-to-treat
(NNT) to produce one outcome will be calculated.
Continuous outcomes
Anticipating different measures across studies, data will be pooled
by calculating the standardised mean difference (SMD), using
95% confidence intervals.
Unit of analysis issues
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Where studies have two relevant experimental conditions to be
compared against a control condition, data will be managed as
follows:
Continuous data -means, SDs andnumber of participants for each
experimental condition will be pooled across the two conditions
as a function of the number of participants in each condition (Law
2003) to be compared against the control condition.
Dichotomous data - active treatment groups will be collapsed into
a single arm for comparison against the control group, or the
control group will be split equally into two.
A similar approach will be used where studies have two relevant
control conditions (e.g. usual care and a waiting-list control con-
dition) to be compared against one experimental condition.
Dealing with missing data
Missing dichotomous data will be managed through intention to
treat (ITT) analysis, in which it will be assumed that patients who
dropped out after randomisation had a negative outcome. Best/
worse case scenarios will also calculated for the clinical response
outcome, in which it will be assumed that dropouts in the active
treatment group had positive outcomes and those in the control
group had negative outcomes (best case scenario), and that drop-
outs in the active treatment group had negative outcomes and
those in the control group had positive outcomes (worst case sce-
nario), thus providing boundaries for the observed treatment ef-
fect.
Missing continuous data will either analysed on an endpoint basis,
including only participants with a final assessment, or analysed us-
ing last observation carried forward to the final assessment (LOCF)
if LOCF data were reported by the trial authors. Where SDs are
missing, attempts will be made to obtain these data through con-
tacting trial authors. Where SDs are not available from trial au-
thors, they will be calculated from t-values, confidence intervals
or standard errors, where reported in articles (Deeks 1997a; Deeks
1997b). If these additional figures are not available or obtainable,
the study data will not be included in the comparison of interest.
Assessment of heterogeneity
Statistical heterogeneity will be formally tested using the natural
approximate chi-square test, which provides evidence of variation
in effect estimates beyond that of chance. Since the chi-squared
test has low power to assess heterogeneity where a small number of
participants or trials are included, the p-valuewill be conservatively
set at 0.1. Heterogeneity will also be tested using the I2 statistic,
which calculates the percentage of variability due to heterogeneity
rather than chance, with I2 values over 50% indicating strong
heterogeneity (Higgins 2008).
Assessment of reporting biases
Where sufficient numbers of trials allow a meaningful presenta-
tion, funnel plots will be constructed to establish the potential
influence of publication bias.
Data synthesis
Data will be entered into RevMan 5.0 software by two review
authors (double data entry). A fixed effect model will be used in
the first instance to combine data. If there is evidence of statistical
heterogeneity, results will be recalculated using a random effects
model, in order to obtain a more conservative estimate.
Subgroup analysis and investigation of heterogeneity
Multiple subgroup analyses will be performed, but interpreted
with caution, due to the risk of false positive conclusions. If pos-
sible, the following subgroup analyses will be performed:
1. Separate anxiety disorders (category 1), stratified as
generalised anxiety disorder, panic disorder and social phobia.
2. Minimal management control condition (waiting list versus
other minimal management control conditions)
3. Other psychological therapy control conditions, stratified as
psychodynamic, interpersonal and supportive therapies
4. CBT versus third wave CBT interventions
5. Group versus individual treatment delivery
6. The age classification of participants (55-79 years versus 80
years and over).
Where there are sufficient studies, these subgroup analyses will
also be used to examine potential sources of clinical heterogeneity.
Sensitivity analysis
Sensitivity analyses will also be undertaken to assess the degree
to which the effect sizes depend on the assumptions made by the
reviewers. Studies will be limited to those of higher quality as
determined by risk of bias domains, including:
1. Allocation concealment
2. Dropout rate lower than 20%
3. Use of formal testing of fidelity to psychological therapy
manual
4. Use of blinded outcome assessors
These sensitivity analyses will also be used to examine potential
sources of methodological heterogeneity.
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A P P E N D I C E S
Appendix 1. Search strategies
The following search strings will be used:
For the CCDANCTR-Studies database: Keyword=”late-life” OR “Elderly” OR “Aged” OR “Old Age” AND Keyword=”Anxiety” OR
“Panic” OR “Agoraphobia” OR “Phobia” OR “Obsessive-compulsive” OR “Posttraumatic” AND Keyword= “psychological therapy”
OR “psychotherapy” OR “cognitive therapy” OR “behavio(u)r(al) therapy” OR “cognitive-behavio(u)r(al) therapy” OR “CBT”
For PubMed: Keyword=”Aged [MESH]” OR “Aged, 80 years and over [MESH]“ AND keyword=”Anxiety disorder [MESH]” AND
Keyword= “behaviour therapy [MESH]”.
For PsycINFO: Keyword=”late-life” OR “Elderly” OR “Aged” OR “Old Age” AND Keyword=”Anxiety disorder [Thesaurus]” AND
Keyword= “cognitive therapy [Thesaurus]” or “psychotherapy [thesaurus]” OR “cognitive behavior therapy [Thesaurus]” OR “behavior
therapy [Thesaurus]”
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